Enemafosfo® (Solvent) Instructions for Use
Marketing Authorization Holder
Melon, LLC (Russia)
Manufactured By
Vertex, JSC (Russia)
ATC Code
A06AG01 (Sodium phosphate)
Active Substances
Sodium dihydrogen phosphate (BP British Pharmacopoeia)
Sodium hydrogen phosphate (Grouping name)
Dosage Form
| Enemafosfo® | Rectal solution 7.2 g+19.2 g/120 ml: bottle 1 pc. complete with cannula |
Dosage Form, Packaging, and Composition
Rectal solution transparent, colorless.
| 1 bottle | |
| Sodium hydrogen phosphate heptahydrate | 7.2 g |
| Sodium phosphate monobasic monohydrate | 19.2 g |
Excipients : sodium benzoate – 0.48 g, concentrated phosphoric acid – to pH 5.0-5.8, purified water – to 120 ml.
120 ml – single-use bottles (1) complete with cannula – cardboard packs.
Clinical-Pharmacological Group
Laxative drug with osmotic properties
Pharmacotherapeutic Group
Laxative
Pharmacological Action
Saline laxative.
The action is based on increasing fluid retention in the intestine through osmotic processes. The accumulation of fluid in the intestine leads to increased peristalsis and subsequent bowel emptying. The effect develops within 5-7 minutes after administration.
Pharmacokinetics
Sodium phosphate is poorly absorbed in the intestine; however, absorption of sodium and phosphate ions does occur and is dose-dependent.
Indications
Constipation; preparation for endoscopic examination of the rectum; preparation for X-ray examination of the abdominal organs; preparation for surgical operations on the abdominal organs, childbirth.
ICD codes
| ICD-10 code | Indication |
| K59.0 | Constipation |
| Z51.4 | Preparatory procedures for subsequent treatment or examination, not elsewhere classified |
| ICD-11 code | Indication |
| DB32.1 | Slow-transit constipation |
| DD91.1 | Functional constipation |
| DE2Z | Diseases of the digestive system, unspecified |
| QB9A | Preparatory procedures for subsequent treatment |
Dosage Regimen
| The method of application and dosage regimen for a specific drug depend on its form of release and other factors. The optimal dosage regimen is determined by the doctor. It is necessary to strictly adhere to the compliance of the dosage form of a specific drug with the indications for use and dosage regimen. |
Administer orally or rectally using the appropriate dosage forms.
For rectal administration, use the entire contents of one 120 ml bottle.
Lie on your left side with knees bent.
Gently insert the provided cannula into the rectum.
Squeeze the bottle to administer the solution.
For oral administration, dilute the entire contents of one bottle in at least 120 ml of cool water.
Stir until completely dissolved and drink immediately.
Follow administration with a full glass of additional water.
For pre-procedural bowel cleansing, use according to a specific medical schedule.
Typically administer the evening before the procedure and repeat on the morning of the procedure.
Do not take other oral medications within one hour of administration.
Maintain adequate fluid intake before, during, and after use.
Do not use for more than one week without medical consultation.
Discontinue use and consult a physician if no bowel movement occurs within 6 hours after oral intake.
Adverse Reactions
Possible allergic reactions, nausea, vomiting, abdominal pain, local irritant effect (irritation around the anus).
Contraindications
Intestinal obstruction, intestinal perforation, acute inflammatory and/or ulcerative lesions of the distal intestines, acute hemorrhoids, anal fissures, age under 18 years, hypersensitivity to the active substances.
Use in Pregnancy and Lactation
Can be used for preparation for childbirth according to indications when the potential benefit outweighs the risk of use. Use during breastfeeding is not recommended.
Use in Renal Impairment
The drug is contraindicated for use in renal impairment.
Pediatric Use
The drug is contraindicated for use in children and adolescents under 18 years of age.
Special Precautions
When using this product, patients should maintain adequate fluid intake. Electrolyte levels should be monitored before and after use.
If no bowel movement occurs within 6 hours after oral administration, the patient should be asked to stop taking this product and consult a doctor, as dehydration may develop.
Drug Interactions
When used rectally, a doctor should be consulted if the patient is taking anticoagulants, digitalis preparations, ciprofloxacin, etidronate, sodium polystyrene sulfonate, or tetracycline antibiotics.
Storage Conditions
Store at 2°C (36°F) to 25°C (77°F). Keep in original packaging, protected from light. Keep out of reach of children.
Dispensing Status
Over-the-Counter
Important Safety Information
This information is for educational purposes only and does not replace professional medical advice. Always consult your doctor before use. Dosage and side effects may vary. Use only as prescribed.
Medical Disclaimer